These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24164966)

  • 1. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
    J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
    Rowbottom MW; Faraoni R; Chao Q; Campbell BT; Lai AG; Setti E; Ezawa M; Sprankle KG; Abraham S; Tran L; Struss B; Gibney M; Armstrong RC; Gunawardane RN; Nepomuceno RR; Valenta I; Hua H; Gardner MF; Cramer MD; Gitnick D; Insko DE; Apuy JL; Jones-Bolin S; Ghose AK; Herbertz T; Ator MA; Dorsey BD; Ruggeri B; Williams M; Bhagwat S; James J; Holladay MW
    J Med Chem; 2012 Feb; 55(3):1082-105. PubMed ID: 22168626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
    Holladay MW; Campbell BT; Rowbottom MW; Chao Q; Sprankle KG; Lai AG; Abraham S; Setti E; Faraoni R; Tran L; Armstrong RC; Gunawardane RN; Gardner MF; Cramer MD; Gitnick D; Ator MA; Dorsey BD; Ruggeri BR; Williams M; Bhagwat SS; James J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5342-6. PubMed ID: 21807507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
    Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
    Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
    Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
    Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
    Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
    Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic
    Miyauchi S; Shien K; Takeda T; Araki K; Nakata K; Miura A; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Suzawa K; Yamamoto H; Okazaki M; Soh J; Tomida S; Yamane M; Sakaguchi M; Toyooka S
    Anticancer Res; 2020 May; 40(5):2667-2673. PubMed ID: 32366411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.